Highest-materiality recent filing
MariMed Q2 2026 revenue up 6% to $41.9M; net loss widens to $3.6M
Revenue of $41.9M in Q2 2026, up 6% from $39.5M in Q2 2025; H1 revenue $81.4M vs $77.4M.
MariMed reports FY2025 revenue of $159.8M, net loss widens to $14.5M, adjusted EBITDA down to $16.9M
FY2025 revenue $159.8M, up from $157.7M in FY2024; Q4 revenue $41.7M vs $38.9M.
MariMed restructures $14.2M Series B obligation with $8M notes and 26.9M preferred shares
Old Series B preferred (4,908,333 shares) cancelled, avoiding ~$14.2M cash payout upon mandatory conversion on Feb 28, 2026.
MariMed Q3 revenue $40.8M, adjusted EBITDA $5.1M; expands brands to 3 new states
Revenue flat at $40.8M (Q3 2024: $40.6M); GAAP net loss widened to $2.9M from $1.0M.
MariMed Q2 revenue $39.6M, adjusted EBITDA $4.9M; net loss narrows YoY
Revenue of $39.6M for Q2 2025, down 2% YoY from $40.4M; GAAP net loss improved to $1.3M from $1.6M.
MariMed Q1 revenue flat at $38.0M; net loss widens to $5.4M from $1.3M YoY
Revenue of $38.0M flat vs $37.9M a year ago; GAAP gross margin fell to 40% from 43%.
MariMed reports record FY2024 revenue $158M; Q4 margins compress, adjusted EBITDA up in Q4
Q4 2024 revenue $39.0M (vs $38.9M); full-year revenue $158.0M (+6.3% YoY).
MariMed Q3 revenue up 5% to $40.6M; net loss narrows to $1.0M
Revenue $40.6M, +5% YoY; adjusted EBITDA $4.7M vs $6.1M in Q3 2023.
MariMed Q2 2024 revenue $40.4M, GAAP net loss $1.6M, adjusted EBITDA $4.4M
Revenue $40.4M, up 10.7% YoY from $36.5M; gross margin 42% (GAAP), 43% (non-GAAP).
MariMed Q1 2024 revenue up 10% to $37.9M; net loss widens to $1.3M, adjusted EBITDA down
Revenue of $37.9M (+10% YoY); GAAP gross margin 43% vs 45% in prior year.
MariMed Q4 revenue $38.9M (+8.6% YoY); GAAP net loss $10.1M; announces MD dispensary acquisition
Q4 2023 revenue $38.9M, up 8.6% from $35.8M in Q4 2022; full year revenue $148.6M, up 10.9% from $134.0M.
MariMed closes $58.7M debt refinancing at 8.43% fixed rate; expects $4.7M savings in first year
10-year loan from Needham Bank with interest-only payments for first 12 months, then 20-year amortization.
MariMed Q3 revenue $38.8M (+14% YoY), GAAP net loss of $4.3M vs profit a year ago
Revenue of $38.8M for Q3 2023, up 14% from $33.9M in Q3 2022.
CFO Susan M. Villare resigns; CEO Jon R. Levine appointed interim CFO
Susan M. Villare resigned as CFO of MariMed Inc., effective October 31, 2023.
MariMed Q2 revenue $36.5M (+11% YoY); GAAP net loss $0.9M vs $1.9M profit
Revenue $36.5M, up 11% from $33.0M year-over-year; wholesale set monthly and quarterly records.
MariMed Q1 revenue up 10% YoY to $34.4M but GAAP net loss of $0.7M vs prior-year profit
Revenue $34.4M vs $31.3M YoY (+10%); GAAP gross margin fell to 45% from 54%.
MariMed appoints Edward Gildea as Chairman and Jon R. Levine as CEO
Edward Gildea appointed Chairman of the Board, effective February 28, 2023.
MariMed Q4 revenue up 15.5% YoY to $35.8M; net income turns positive but EBITDA margin shrinks
Q4 revenue $35.8M (+15.5% YoY); full-year revenue $134.0M (+10.3% YoY).
MariMed closes $35M credit facility with Chicago Atlantic to fund expansion and acquisitions
Borrowed $30M at close of $35M secured credit facility; can draw additional $5M over six months.
MariMed appoints Jon Levine as Interim CEO after passing of Robert Fireman
Jon Levine, previously President, named Interim CEO effective immediately; retains President role.
MariMed CEO and Chairman Robert Fireman dies unexpectedly on Dec 11
Robert Fireman, CEO since 2017 and co-founder, passed away unexpectedly on Dec 11, 2022.
MariMed Q3 revenue $33.9M (+2% YoY); adjusted EBITDA falls 32% to $8.6M
Revenue $33.9M vs $33.2M in Q3 2021, a 2% YoY increase.
MariMed Q2 revenue $33.0M (+1% YoY); GAAP net income falls 75% to $1.9M
Revenue $33.0M vs $32.6M year ago; gross margin dropped to 45% from 60%.
MariMed appoints Susan Villare as CFO; Jon Levine promoted to CAO
Susan Villare named CFO effective May 11, 2022; succeeds Jon Levine.
MariMed Q1 revenue up 27% to $31.3M; adj EBITDA $10.4M, guidance reaffirmed
Revenue $31.3M (up 27% YoY); gross margin 54.3% vs 53.5%; net income $4.2M (flat YoY).
MariMed gets Maryland approval to acquire Kind Therapeutics; over 139K patients in state program
MMCC approved transfer of 100% ownership of Kind Therapeutics to MariMed on April 13, 2022.
MariMed agrees to acquire Kind Therapeutics USA for $20M; buys minority interests for $2M
Acquires 100% of Kind Therapeutics for $20M: $13.5M cash, $6.5M in 4-year 6% promissory notes.
MariMed Q2 revenue $32.6M (+239% YoY); raises FY2021 guidance to $118M revenue, $32M EBITDA
Revenue $32.6M, up 239% YoY and 32% QoQ; net income $7.6M vs loss $1.1M in Q2 2020.
MariMed signs 3-year employment deals for CEO, CFO, COO with base salaries and option grants
CEO Robert Fireman, CFO Jon Levine, COO Timothy Shaw each entered new 3-year employment agreements effective July 1, 2021.
Effective August 9, 2024, MariMed Inc. (the “Company”) appointed Mario Pinho as the Company's Chief Financial Officer to replace Jon Levine, the Company's Interim Chief Financial Officer.
Effective October 31, 2023 Susan M. Villare resigned as the Chief Financial Officer of MariMed Inc.
The Board of Directors has appointed Jon R. Levine, the Company's President and Chief Executive Officer, as the Company's Interim Chief Financial Officer
Effective April 17, 2023, Kathleen Tucker was appointed to the Board of Directors (the “Board”) of MariMed Inc. (the “Company”).
Effective September 7, 2022 (the “ Effective Date ”), MariMed Inc. (the “ Company ”) promoted Jon Levine, Chief Administrative Officer of the Company, to President of the Company replacing Robert Fireman in that position (the “ Promotion ”).
Effective September 7, 2022 (the “ Effective Date ”), MariMed Inc. (the “ Company ”) promoted Jon Levine, Chief Administrative Officer of the Company, to President of the Company replacing Robert Fireman in that position (the “ Promotion ”).
Jon Levine, the Chief Financial Officer of the Company at the time of her appointment, was promoted to the position of Chief Administrative Officer of the Company.
the Company appointed Susan M. Villare as the Company’s Chief Financial Officer.
Max materiality 0.85 · Median 0.65 · Most common event earnings